Against the backdrop of September 11th terrorist attacks in the U.S., the anthrax attacks in late 2001 raised highly controversial issues related to intellectual property rights. Just a few months earlier, the world had witnessed heated debates on the patent controversy when the Pharmaceutical Manufacturers’ Association of South Africa (PMASA), a body representing South African subsidiaries of 39 drug transnational corporations (TNCs), took the South African government to court to prevent it from importing cheaper versions of patented drugs for patients suffering from Acquired Immuno Deficiency Syndrome (AIDS). However, under tremendous pressure generated by health activists and concerned groups around the world, the drug TNCs unconditionally dropped the lawsuit against the South African government.
HIV/AIDS Global Trust Fund: Need for an Equitable and Efficient Governance Structure
The international community appears poised to intervene to end the devastating effects of the HIV/AIDS epidemic, especially in Africa where, according to the United Nations Agency for HIV/AIDS (UNAIDS), more than 25 million Africans live with the virus or are dying of AIDS. Few infected Africans have access to life saving anti-HIV/AIDS medicines that have transformed the disease from a feared to a manageable chronic infection in the West. Through a combination of street protests, sophisticated policy reviews, media exposes, and powerful commentaries in the print and electronic media, AIDS activists have forced the issue of access to HIV/AIDS care in developing nations.
We Do Guns–Not Plagues
We now face, with the global spread of AIDS, a human catastrophe that is beyond history. We have never witnessed anything so devastating. In sub-Saharan Africa, there is a pandemic that threatens to exceed the toll that the Bubonic Plague took on Europe in ushering in the Dark Ages. 23 million people are infected in Sub-Saharan Africa, with new infections coming at the rate of roughly five thousand a day.
AIDS and Developing Countries: Democratizing Access
International Tobacco Sales (revised Oct 2000)
Key Points
